What is bristol myers squibb

Bristol Myers Squibb Co reported second quarter earnings that topped Wall Street estimates, as sales of flagship cancer treatment Opdivo returned to growth after missing estimates in the previous quarter.

Bristol-Myers Squibb Co and Eisai Co on Thursday entered into an agreement to jointly develop and market an experimental cancer drug. Bristol Myers Squibb said on Thursday the U. Food and Drug Administration approved its oral drug Zeposia to treat adults with ulcerative colitis, a chronic inflammatory bowel disease.

An immunotherapy showed for the first time it can help early-stage lung cancer patients survive longer without their disease returning, according to data on Wednesday, a potential turning point for such drugs to be used before tumours spread.

An experimental Bristol Myers Squibb drug from a new class of immunotherapy used in combination with its big-selling cancer medicine Opdivo significantly extended the time it took for advanced melanoma to worsen compared with Opdivo alone, according to early data from a Bristol Myers Squibb Co reported lower-than-expected first-quarter profit on Thursday as sales of its high margin cancer drugs Revlimid and Opdivo fell short of Wall Street estimates. The U. Quote and financial data from Refinitiv.

Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes. Latest Trade Change Volume 8,, Today's Range Pricing Previous Close. Today's High. Today's Low. Moving forward. Learn more about how we strive to produce sustained strong performance and shareholder value. Looking for Answers? Quick links to helpful resources. Clinical Trial Information for Researchers. Clinical trials and research are a critical part of bringing new medicines to patients.

Medical Information for Healthcare Providers. In , it introduced Blenoxane bleomycin sulfate for squamous cell cancers, head and neck cancers, and non-Hodgkins lymphomas; followed in with Mutamycin mitomycin for bone cancer and stomach and pancreas tumors; in with Ceenu lomustine , a chemotherapy product for brain cancer and Hodgkins lymphoma; in with Bicnu carmustine , for treatment of brain and lymphatic cancers; and in with anticancer agents Platinol and Lysodren mitotane.

The 70s was also a decade of success for Squibb, when its researchers Miguel Ondetti and David Cushman created Capoten captopril , which was the first in a new class of high blood pressure agents called ACE angiotensin-converting enzyme inhibitors.

Capoten was an important new medical discovery for the treatment of patients with high blood pressure. Bristol-Myers merged with Squibb in , creating the global leader in healthcare that we know today.

It was the combination of two strengths that has propelled BMS into the top 20 list of pharmaceutical companies of the world. In , BMS agreed to a number of acquisitions and licensing partnerships. The first was an agreement with KAI Pharmaceuticals to globally develop and commercialize a therapy for cardiovascular diseases. This acquisition enhanced the pipeline as it brought compounds in two important classes of anticancer agents to the table.

The final collaboration in was with San Francisco-based Exelixis to develop and commercialize two novel therapies: one for medullary thyroid cancer and the other as a treatment for advanced solid tumor malignancies. In , more partnerships were arranged.